Lung Cancer Liquid Biopsy Market Expected to Grow at a CAGR of 12.7% by 2032 | Persistence Market Research Analysis

Overview of the Lung Cancer Liquid Biopsy Market

The global lung cancer liquid biopsy market is expected to grow from USD 824.7 million in 2025 to USD 1,900.5 million by 2032, with a compound annual growth rate (CAGR) of 12.7%. This growth is primarily driven by the increasing prevalence of lung cancer and the rising demand for non-invasive diagnostic methods. Liquid biopsy, which analyzes blood-based biomarkers like cell-free DNA (cfDNA), circulating tumor cells (CTCs), and exosomes, offers a promising alternative to conventional tissue biopsies. This method enables earlier detection, better monitoring of disease progression, and more personalized treatment plans.

As a non-invasive method, liquid biopsy provides significant advantages over traditional biopsies, particularly in detecting genetic mutations associated with lung cancer. The technique's ability to identify alterations such as EGFR mutations or ALK rearrangements allows clinicians to tailor therapies more precisely, leading to improved outcomes for patients. North America has been the leading region in adopting liquid biopsy technologies, owing to high lung cancer incidence and advanced healthcare infrastructure. Asia-Pacific, particularly China and Japan, is also rapidly expanding in this field, with increasing adoption of liquid biopsy technologies.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.persistencemarketresearch.com/samples/35195

Key Highlights from the Report

• NGS-based multi-gene parallel analysis dominated the global market in 2024, offering comprehensive genomic profiling.
• Whole Genome Amplification (WGA) and Digital PCR technologies are enhancing sensitivity in detecting low-abundance mutations, improving early detection.
• North America held the largest market share in 2024 due to high lung cancer prevalence and advanced healthcare infrastructure.
• Asia-Pacific is expected to be the fastest-growing region, with China and Japan leading adoption.
• MicroRNAs are being explored as potential biomarkers for early lung cancer detection.
• Collaborative networks between hospitals, research centers, and biotech companies are accelerating liquid biopsy technology development.

Market Segmentation

The lung cancer liquid biopsy market can be segmented based on product type, technology, end-user, and geography.

1. Product Type: Consumables, including test kits, reagents, and assay components, accounted for 71.2% of the market share in 2024. These consumables are integral to diagnostic procedures, as they are essential for collecting, processing, and analyzing samples. With the growing adoption of liquid biopsy technologies for lung cancer detection, the demand for consumables like test kits and reagents is expected to continue rising.

2. Technology: In terms of technology, NGS-based multi-gene parallel analysis dominated the market with a 75.2% market share in 2024. NGS allows for the simultaneous analysis of multiple genetic mutations, providing detailed molecular insights that help in both diagnosis and personalized treatment. NGS has become the preferred technology due to its ability to detect a wide range of genetic alterations, making it a critical tool for clinicians in lung cancer diagnostics.

Regional Insights

1. North America: North America remains the dominant region in the lung cancer liquid biopsy market, driven by a high lung cancer incidence rate and a robust healthcare infrastructure. The U.S. market, in particular, benefits from advanced diagnostic technologies and a well-established healthcare system. Additionally, the increasing adoption of precision medicine and the availability of cutting-edge diagnostic tools are expected to propel the growth of liquid biopsy technologies in this region.

2. Asia-Pacific: The Asia-Pacific region, particularly China and Japan, is emerging as a fast-growing market for lung cancer liquid biopsy. The rising prevalence of lung cancer, along with increasing healthcare investments and growing awareness of advanced diagnostic technologies, is fueling market growth in these countries. Moreover, advancements in healthcare infrastructure and government initiatives to improve cancer diagnosis are expected to contribute significantly to the adoption of liquid biopsy in this region.

Market Drivers

The key drivers of the lung cancer liquid biopsy market include:

1. Advances in Liquid Biopsy Technologies: Recent advancements in technologies like Next-Generation Sequencing (NGS), PCR-based methods, and digital PCR have significantly improved the sensitivity and accuracy of liquid biopsy tests. These advancements allow for earlier and more accurate detection of lung cancer, enabling clinicians to intervene at the earliest possible stage.

2. Rising Prevalence of Lung Cancer: The increasing incidence of lung cancer worldwide has heightened the demand for early diagnostic methods. Lung cancer remains one of the leading causes of cancer-related deaths globally, making early detection and intervention critical for improving patient outcomes.

3. Demand for Non-Invasive Diagnostic Methods: Liquid biopsy offers a non-invasive alternative to traditional tissue biopsy, making it an attractive option for patients. Its ability to provide critical genetic information through a blood sample reduces the need for more invasive and risky procedures, driving adoption in clinical practice.

Market Restraints

Despite its promise, the lung cancer liquid biopsy market faces several challenges:

1. Limited Sensitivity for Early-Stage Cancers: One of the primary limitations of liquid biopsy is its ability to detect early-stage cancers. The concentration of tumor-derived biomarkers, such as ctDNA or CTCs, is often very low in early stages of the disease, making it challenging to detect the cancer at its most treatable stages.

2. High Cost and Lack of Standardization: The high cost of liquid biopsy tests and the lack of standardized protocols for sample collection, processing, and analysis remain significant barriers to widespread adoption. These challenges may limit the accessibility of liquid biopsy in certain regions, particularly in low-income countries.

3. Complexity of Tumor Biology: The diversity of tumor biology and the variability in biomarker expression pose challenges in accurately identifying early-stage lung cancer through liquid biopsy. Continuous advancements in biomarker discovery and technology are needed to address these complexities.

Market Opportunities

There are significant opportunities for growth in the lung cancer liquid biopsy market:

1. Increasing Demand for Companion Diagnostics: Liquid biopsy is increasingly being used as a companion diagnostic tool to identify patients who are likely to benefit from targeted therapies. This trend is expected to drive further market expansion, as liquid biopsy plays a crucial role in personalized medicine, particularly in lung cancer.

2. Technological Innovations: The development of more sensitive technologies such as Whole Genome Amplification (WGA) and digital PCR presents significant opportunities for the market. These technologies offer ultra-sensitive and precise detection of low-abundance mutations, which is crucial for early cancer detection.

3. Collaboration and Funding: Expanding collaborations between research institutions, biotech companies, and healthcare providers is helping accelerate the development and adoption of liquid biopsy technologies. Moreover, increased funding for research in biomarker discovery and liquid biopsy validation will further boost the market.

Reasons to Buy the Report

✔ Comprehensive Analysis: The report provides an in-depth analysis of market trends, dynamics, and forecasts for the lung cancer liquid biopsy market.
✔ Market Segmentation Insights: It includes detailed insights into the market segmentation based on product type, technology, and end-users, offering actionable information for decision-makers.
✔ Competitive Landscape: The report outlines the key players in the market, helping businesses understand their position and strategies.
✔ Regional Market Trends: It offers a thorough analysis of the key regional markets, identifying growth opportunities and challenges in different geographies.
✔ Strategic Recommendations: The report includes strategic recommendations to help businesses capitalize on the emerging trends in the lung cancer liquid biopsy market.

Company Insights

Key players in the lung cancer liquid biopsy market include:

• Foundation Medicine, Inc.
• Guardant Health, Inc.
• Thermo Fisher Scientific
• BioMark Diagnostics
• Freenome, Inc.
• QIAGEN N.V.
• Roche Diagnostics

Recent Developments:

1. Foundation Medicine received U.S. FDA approval for its FoundationOne®Liquid CDx test as a companion diagnostic tool for targeted therapies in lung cancer.

2. Freenome launched the PROACT LUNG clinical study in December 2023, validating its blood test for early lung cancer detection using a multiomics platform.

In conclusion, the lung cancer liquid biopsy market is poised for significant growth, driven by technological advancements, increasing lung cancer prevalence, and rising demand for non-invasive diagnostics. With continued innovation and collaboration, the market is expected to thrive in the coming years, offering improved diagnostic and treatment options for patients worldwide.

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

This release was published on openPR.